Brought to you by 
Cadence grosses $86.6mm via private financing
22 Apr 2009
Executive Summary
Hospital products company Cadence Pharmaceuticals grossed $86.6mm through the private sale of about 12mm common shares at $7.13 each (a 5% discount). Venrock led and was joined by Frazier Healthcare Ventures, Domain Associates, Versant Ventures, New Enterprise Associates, Bay City Capital, and T. Rowe Price Associates. The shareholders also paid $0.125 apiece for 6mm warrants, which can be exercised until February 18, 2014, and entitle the investors to buy common stock at $7.84/share.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cadence grosses $86.6mm via private financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice